Ionizing radiation induces BH4 deficiency by downregulating GTP-cyclohydrolase 1, a novel target for preventing and treating radiation enteritis.

Radiation enteritis (RE) is a common side effect after radiotherapy for abdominal cancer. RE pathogenesis is complicated, with no drugs available for prevention or treatments. Intestinal ischemia is a key factor in the occurrence and development of enteritis. The effect of ionizing radiation (IR) on intestinal ischemia is unknown. Deficiency of tetrahydrobiopterin (BH4) produced by GTP-cyclohydrolase 1 (Gch1) is important in ischemic diseases. This study focused on the relationship of Gch1/BH4 between intestinal ischemia in radiation enteritis. BH4 levels were analyzed by high-performance liquid chromatography in humans and rats after radiotherapy. Intestinal blood perfusion was measured by laser doppler flow imaging. Vascular ring tests determined the diastolic functions of rat mesenteric arteries. Gene, protein, and immunohistochemical staining experiments and inhibitor interventions were used to investigate Gch1 and endothelial NOS (eNOS) in rat mesenteric arteries and endothelial cells. The results showed that IR decreased BH4 levels in patients and rats after radiotherapy and decreased intestinal blood perfusion in rats. The degree of change in intestinal ischemia was consistent with intestinal villus injury. Gch1 mRNA and protein levels and nitric oxide (NO) production significantly decreased, while eNOS uncoupling in arterial and vascular endothelial cells strongly increased. BH4 supplementation improved eNOS uncoupling and NO levels in vascular endothelia after IR. The results of this study showed that downregulation of Gch1 in intestinal blood vessels after IR is an important target in RE. BH4 supplementation may prevent intestinal ischemia and improve vascular endothelial function after IR. These findings have clinical significance for the prevention and treatment of RE.

GTP-Cyclohydrolase I deficiency presenting as malignant hyperphenylalaninemia, recurrent hyperthermia and progressive neurological dysfunction in a South Asian child - a case report.

BACKGROUND: Tetrahydrobiopterin (BH4) deficiencies are disorders affecting phenylalanine homeostasis, and catecholamine and serotonin biosynthesis. GTP-Cyclohydrolase I deficiency (OMIM 600225) is an extremely rare variant of inborn error of BH4 synthesis which exists in recessive and dominant forms. The recessive form presents with complex neurological and autonomic dysfunction whilst the dominant form presents as Dopa-responsive dystonia. CASE PRESENTATION: We describe a South Asian child who initially presented with neurological dysfunction and recurrent vomiting and later developed recurrent hyperthermia for several months. The child did not have screening for hyperphenylalaninemia at birth and was found to have marked hyperphenylalaninemia after clinical presentation at 5 months. Further evaluation revealed BH4 deficiency. GTP-Cyclohydrolase I deficiency (GTPCH) was identified based on normal dihydro pteridine reductase activity and markedly reduced neopterin in dried blood spot test. After institution of treatment and control of high phenylalanine levels, clinical deterioration decelerated yet with noticeable residual neurological dysfunction. CONCLUSION: To authors' knowledge, this is first report of GTPCH deficiency in a South Asian child. The case highlights practical issues regarding diagnosis of GTPCH deficiency, especially in countries without broader universal newborn screening programs for early detection of inherited metabolic disorders. Testing for GTPCH deficiency should be considered for patients with unexplained neurological and autonomic symptoms following initial metabolic screen.

Fenilcetonúria: aspectos genéticos, diagnóstico e tratamento / Phenylketonuria: genetic aspects, diagnosis and treatment

A fenilcetonúria é uma doença genética e metabólica, com bom prognóstico caso seja detectada e tratada precocemente. É a mais frequente entre os distúrbios metabólicos com significativa implicação clínica. Ela é detectada precocemente pelo Teste do Pezinho na triagem neonatal, e o tratamento padrão consiste em dieta restritiva. Este estudo teve por finalidade informar e atualizar os profissionais da área da saúde sobre base genético-clínica da fenilcetonúria, com destaque para sua etiologia e aconselhamento genético; diagnóstico com enfoque no histórico da triagem neonatal; e tratamento − em especial o dietético. Foi utilizada como fonte a literatura científica especializada, publicada principalmente nos últimos 5 anos.(AU)

Phenylketonuria is a genetic and metabolic disease, with good prognosis if early detected and treated. It is the most frequent among metabolic disorders, with significant clinical implications. It is detected early by Guthrie test in the neonatal screening, and the standard treatment consists of a restrictive diet. This study is aimed at informing and updating healthcare professionals on: 1) genetic-clinical basis of phenylketonuria, highlighting its etiology and genetic counseling, 2) diagnosis focusing on the history of newborn screening, and 3) treatment, in particular the dietetic one. The specialized scientific literature, particularly that published in the last five years, was used as a source.(AU)

Epidemiology in a changing world: variation, causation and ubiquitous risk factors.

We are all living in the era of globalization and, like it or not, it is going to change the way we practise epidemiology, the kinds of questions we ask and the methods we use to answer them. However, the methods, and ways of thinking about the health of populations, that will be required for epidemiology in the 21st century are in some instances quite different from the standard epidemiological techniques that are taught in most textbooks and courses today. As we develop epidemiological methods for addressing the scientific and public health problems of the 21st century, it is important that we consider, once again, the distinction between the analysis of variance and the analysis of causes. This has primarily been considered with respect to genetic research, and also with regard to the problems of making comparisons between different populations and environments at the same point in time. It has not been considered in depth with regard to the issues of conducting epidemiological research in a world that is changing over time. In this article, I first consider the statistical and scientific issues involved in the distinction between the analysis of variance and the analysis of causes. I then discuss some examples of the implications of this distinction for the theory and practice of epidemiology in a changing world, particularly with regard to risk factors that become ubiquitous over time. Sometimes the most important causes of disease are invisible because they are everywhere.

Urinary metabolic profile of phenylketonuria in patients receiving total parenteral nutrition and medication.

Nutrition and drugs are main environmental factors that affect metabolism. We performed metabolomics of urine from an 8-year-old patient (case 1) with epilepsy and an 11-year-old patient (case 2) with malignant lymphoma who was being treated with methotrexate. Both patients were receiving total parenteral nutrition (TPN). We used our diagnostic procedure consisting of urease pretreatment, partial adoption of stable isotope dilution, gas chromatography/mass spectrometry (GC/MS) measurement and target analysis for 200 analytes including organic acids and amino acids. Surprisingly, their metabolic profiles were identical to that of phenylketonuria. The neopterin level was markedly above normal in case 1, and both neopterin and biopterin were significantly above normal in case 2. Mutation analysis of genomic DNA from case 1 showed neither homozygosity nor heterozygosity for phenylalanine hydroxylase deficiency. The metabolic profiles of both cases were normal when they were not receiving TPN. TPN is presently prohibited for individuals who have inherited disorders that affect amino acid metabolism. Although the Phe content of the TPN was not the sole cause of the PKU profile, its effect, combined with other factors, e.g. specific medication or possibly underlying diseases, led to this metabolic abnormality. The present study suggests that GC/MS-based metabolomics by target analysis could be important for assuring the safety of the treatments for patients receiving both TPN and methotrexate. Metabolomic profiling, both before and during TPN, is useful for determining the optimal nutritional formula not only for neonates, but also for young children who are known heterozygotes for metabolic disorders or whose status is unknown.

Leukoencephalopathies associated with inborn errors of metabolism in adults.

The discovery of a leukoencephalopathy is a frequent situation in neurological practice and the diagnostic approach is often difficult given the numerous possible aetiologies, which include multiple acquired causes and genetic diseases including inborn errors of metabolism (IEMs). It is now clear that IEMs can have their clinical onset from early infancy until late adulthood. These diseases are particularly important to recognize because specific treatments often exist. In this review, illustrated by personal observations, we give an overview of late-onset leukoencephalopathies caused by IEMs.

High protein diet mimics hypertyrosinemia in newborn infants.

Tyrosinemia resulting from administration of protein-dense infant diets was detected by newborn screening in two infants. Change of formula resulted in rapid resolution of the hypertyrosinemia. These cases identify nonstandard infant diets as a benign and reversible cause of tyrosinemia and a potential cause of positive newborn phenylketonuria screening.

[Follow up protocol of patients with hyperphenylalaninemia]. / Pauta de seguimiento para pacientes con hiperfenilalaninemia.

The protocol of treatment and follow-up of diagnosed as hyperphenylalaninemia (4 mg/dl) by neonatal screening patients, is presented. When admission to the Reference Center for Cataluña in relation to their concentration of phenylalanin in plasma. The only infants who receive restricted in this aminoacid diet, are those with plasma concentrations greater than 10 mg/dl.

[Nutrition and metabolic diseases with a mass incidence]. / Nutrice a metabolická onemocnení hromadného výskytu.

Metabolic diseases with a mass incidence (simple obesity, arterial hypertension, hyperlipoproteinaemia, type II diabetes and gout) are the main risk factors for the manifestation of cardiovascular diseases which can be influenced, as has been reliably proved. They are at present the cause of 56% of all deaths in Czechoslovakia. It is important to emphasize that we are living and dying in an epidemic of cardiovascular diseases. The founder of morbid anatomy, Rudolf Virchow, stated more than 100 years ago: "If the prevalence of a certain disease in a population becomes epidemic, it reflects always a disorder of human culture". It is a fact that a great proportion of the population in Czechoslovakia has adopted during the past decades and still practices an unsound dietary regime and there are other negative lifestyle factors (obesity, smoking, little exercise, high alcohol consumption) for which we pay at present by a declining life expectancy, unnecessary human suffering and the nation as a whole by immense economic losses. The question arises: who and what prevents us from starting in Czechoslovakia as rapidly as possible expedient, comprehensively conceived prevention on a wide front, making use of all findings and advances of world science in this field?

Malignant phenylketonuria due to defective synthesis of dihydrobiopterin.

A defect in the synthesis of dihydrobiopterin was detected in an Arab girl, ascertained through high blood phenylalanine level on neonatal screening. An oral loading test with tetrahydrobiopterin (BH4) caused a significant fall in her blood phenylalanine and a rise in tyrosine concentrations. Her blood biopterin levels were low. In urine and cerebrospinal fluid (CSF) very high neopterin and low biopterin levels were observed. A deficiency of metabolites of neurotransmitters, serotonin and dopamine, was observed in CSF and urine. The patient was given replacement therapy of BH4, 5-hydroxytryptophan, and L-dopa with carbidopa starting from the age of 16 to 18 weeks. On this treatment the blood phenylalanine levels dropped to the desired range, while in urine and CSF a satisfactory rise of neurotransmitter metabolites was observed. In spite of this biochemical control, the patient developed neurological symptoms with myoclonic jerks and changes in muscle tone and presented severe cerebral damage with mental retardation. She died suddenly at the age of 38 weeks.

[Malignant phenylketonuria caused by biopterin synthetase deficiency. Study of neuromediator catabolites in the cerebrospinal fluid during treatment]. / Phénylcétonurie maligne par déficit en bioptérine synthétase. Etude des catabolites des neuro-médiateurs dans le LCR au cours du traitement.

In a child presenting with malignant phenylketonuria due to dihydrobiopterin synthetase deficiency, the authors studied the cerebrospinal fluid (CSF) homovanillic acid and 5 hydroxyindole acetic acid levels under different circumstances: without treatment; under a treatment with tetrahydrobiopterin used alone at various doses; under a treatment associating BH4, L-dopa, 5 hydroxytryptophan and carbidopa, with increasing doses and varying administration schedules. This biological study compared with clinical evolution, shows clearly the inefficacy, regardless of the doses, of BH4 on the CSF levels of neuromediators and on the neurological status, and the excellent efficacy of neuromediator precursors provided high doses are given, divided in the nyctohemeral period.

Tetrahydrobiopterin therapy of atypical phenylketonuria due to defective dihydrobiopterin biosynthesis.

A patient with atypical phenylketonuria (defective BH2 synthesis), detected at age 6 months because of severe muscle hypotonia and serum phenylalanine of 20 mg/100 ml, had normal activities of phenylalanine-4-hydroxylase and DHPR in liver biopsy, but only 2% activity in the phenylalanine-4-hyroxylase in vivo test using deuterated phenylalanine. After IV administration of 2.5 mg/kg chemically pure tetrahydrobiopterin bishydrochloride (BH4 . 2HCl), serum phenylalanine decreased from 20.4 to 2.1 mg/100 ml within 3 hours. Administration of 25 mg BH4 . HCl and 100 mg ascorbic acid through a gastric tube decrease; serum phenylalanine from 13.7 to less than 1.6 mg/100 ml within 3 hours and it remained less than 2 mg/100 ml for 2 days.

Phenylketonuria due to a deficiency of dihydropteridine reductase.

The onset of neurologic symptoms in a child who had markedly elevated blood phenylalanine levels during the first two weeks of life and who was promptly treated with a low phenylalanine diet, with excellent control of serum phenylalanine levels, suggested that this child had an unusual form of phenylketonuria. In assays of the components of the phenylalanine hydroxylating system (open liver biopsy at 14 months), the activity of phenylalanine hydroxylase was 20 per cent of the average normal adult value. By contrast, no dihydropteridine reductase activity was detected in the patient's liver, brain or cultured skin fibroblasts. Since dihydropteridine reductase is also essential for the biosynthesis of dopamine, norepinephrine, and serotonin, disturbed neurotransmitter function may be responsible for the patient's neurologic deterioration. On the basis of these results, assay of reductase in cultured skin fibroblasts may be advisable in the initial diagnosis of phenylketonuria.